Advair 500/50 sNDA “not approvable”
Executive Summary
GlaxoSmithKline's sNDA for Advair Diskus (fluticasone/salmeterol inhalation powder) 500/50 mcg is "not approvable" for an expanded chronic obstructive pulmonary disease indication. In an Aug. 6 letter, FDA questions how the higher-dosing form of the long-acting beta agonist bronchodilator compares with the approved Advair 250/50 mcg strength. GSK does not have head-to-head data comparing the two formulations, the firm tells "The Pink Sheet." FDA's Pulmonary-Allergy Drugs Advisory Committee issued a mixed review of the product May 1, voting 9-2 that GSK's pivotal trial failed to provide "substantial convincing evidence" that the 500/50 dose increased COPD survival (1"The Pink Sheet" May 7, 2007, p. 12)...
You may also be interested in...
Advair Survival Claim In Question; Data Not Robust, But Can’t Confirm – Cmte.
In reaching a decision about whether to approve a survival claim GlaxoSmithKline's Advair,FDA will have to weigh the Pulmonary-Allergy Drugs Advisory Committee's concerns about the robustness of the findings of the single trial that has been conducted with the panel's predictions that it may be impossible to conduct a confirmatory survival study
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.